atomoxetine hydrochloride has been researched along with Sleep Wake Disorders in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Charman, T; Findon, JL; Howes, OD; King, BH; Loth, E; McAlonan, GM; McCracken, JT; Murphy, DG; Parr, JR; Povey, C; Rogdaki, M; Santosh, P; Simonoff, E; Wallace, S; Wichers, RH | 1 |
| Anagnostou, E | 1 |
| Colcher, A; Duda, JE; Horn, SS; Hurtig, HI; Mamikonyan, E; Mavandadi, S; Nazem, S; Siderowf, AD; Stern, MB; Ten Have, TR; Weintraub, D | 1 |
| Hlavaty, L; Stein, MA; Weiss, M | 1 |
| Banaschewski, T; Buitelaar, J; Coghill, D; Cortese, S; Danckaerts, M; Dittmann, RW; Graham, J; Holtmann, M; Sergeant, J; Taylor, E | 1 |
4 review(s) available for atomoxetine hydrochloride and Sleep Wake Disorders
| Article | Year |
|---|---|
Autism spectrum disorder: Consensus guidelines on assessment, treatment and research from the British Association for Psychopharmacology.
Topics: Animals; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Brain; Consensus; Guanfacine; Humans; Melatonin; Methylphenidate; Psychopharmacology; Sleep Wake Disorders | 2018 |
Clinical trials in autism spectrum disorder: evidence, challenges and future directions.
Topics: Adrenergic alpha-Agonists; Adrenergic Uptake Inhibitors; Aggression; Antipsychotic Agents; Aripiprazole; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Autism Spectrum Disorder; Central Nervous System Depressants; Central Nervous System Stimulants; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Irritable Mood; Melatonin; Metformin; Methylphenidate; Obesity; Outcome Assessment, Health Care; Precision Medicine; Risperidone; Sleep; Sleep Wake Disorders | 2018 |
ADHD treatments, sleep, and sleep problems: complex associations.
Topics: Adrenergic alpha-2 Receptor Agonists; Adrenergic Uptake Inhibitors; Antipsychotic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Humans; Propylamines; Sleep; Sleep Wake Disorders | 2012 |
Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.
Topics: Adolescent; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Blood Pressure; Body Size; Cardiovascular Diseases; Central Nervous System Stimulants; Child; Clonidine; Dextroamphetamine; Growth Disorders; Guanfacine; Heart Rate; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Propylamines; Psychoses, Substance-Induced; Seizures; Sleep Wake Disorders; Substance-Related Disorders; Suicide Prevention; Tic Disorders; Treatment Outcome | 2013 |
1 trial(s) available for atomoxetine hydrochloride and Sleep Wake Disorders
| Article | Year |
|---|---|
Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease.
Topics: Adrenergic Uptake Inhibitors; Aged; Atomoxetine Hydrochloride; Cognition Disorders; Comorbidity; Depression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease; Propylamines; Psychiatric Status Rating Scales; Severity of Illness Index; Sleep Wake Disorders; Time Factors; Treatment Outcome | 2010 |